Abbott Gains Diabetes Tech Expansion Opportunity Following Earnings Beat and Insider Sale

Abbott Laboratories (NYSE:ABT) is one of the 12 Set-It-and-Forget-It Stocks to Buy Now.

Amid a positive second quarter and a top executive sale, the company gains an expansion opportunity from Medtronic.

Abbott Laboratories (NYSE:ABT) reported a 6.9% increase in sales for the second quarter of 2025. The earnings report, announced on July 17, 2025, also highlighted an Adjusted EPS of $1.26, which beat the consensus estimates. The company is also making progress in its biosimilars portfolio and anticipates multiple launches in 2026.

Following the second quarter results, the company’s Executive Vice President and Chief Financial Officer, Philip P Boudreau, sold 5,550 shares on August 11, 2025, in a transaction valued at $746,752, signaling negative sentiment. However, on September 2, 2025, the FDA cleared Medtronic’s MiniMed 780G system. The system involves an integration with Abbott Laboratories (NYSE:ABT)’s Instinct sensor. It presents the company with an opportunity to expand its diabetes technology.

With a significant market cap of $232.44 billion, reflecting a strong foothold in the industry, Abbott Laboratories (NYSE:ABT) is a solid choice for long-term, low-maintenance investors.

Abbott Laboratories (NYSE:ABT) is a diversified global healthcare leader. With headquarters in Illinois, the company has been in operation since 1888. It develops, manufactures, and sells a wide range of medical devices, diagnostics, nutritional products, and established branded generic pharmaceuticals worldwide.

While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 High-Risk High-Reward Growth Stocks to Buy Right Now and 12 Stocks with Consistent Growth to Invest In.

Disclosure. None.